Palmitoleic acid

Catalog No.S3341 Synonyms: POA, Palmitoleate

For research use only.

Palmitoleic acid (POA, Palmitoleate) stimulates the uptake of glucose in liver through activation of AMPK and FGF-21, dependent on PPARα.

Palmitoleic acid Chemical Structure

CAS No. 373-49-9

Purity & Quality Control

Choose Selective AMPK Inhibitors

Other AMPK Products

Biological Activity

Description

Palmitoleic acid (POA, Palmitoleate) stimulates the uptake of glucose in liver through activation of AMPK and FGF-21, dependent on PPARα.

Targets
AMPK [1]
()
FGF-21 [1]
()

Protocol (from reference)

Chemical Information

Molecular Weight 254.41
Formula

C16H30O2

Density 0.852 g/mL
CAS No. 373-49-9
Storage 2 years 4°C liquid

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03305809 Completed Drug: LY3154207|Drug: Placebo Lewy Body Dementia Eli Lilly and Company November 9 2017 Phase 2
NCT02682849 Completed -- Retained Blood Syndrome John M. Stulak|Mayo Clinic May 10 2016 --

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Palmitoleic acid | Palmitoleic acid supplier | purchase Palmitoleic acid | Palmitoleic acid cost | Palmitoleic acid manufacturer | order Palmitoleic acid | Palmitoleic acid distributor